Gilead Sciences Given Average Recommendation of “Buy” by Analysts (NASDAQ:GILD)
Shares of Gilead Sciences (NASDAQ:GILD) have been given a consensus rating of “Buy” by the thirty-four analysts that are presently covering the company, Stock Ratings Network.com reports. Two investment analysts have rated the stock with a hold rating and twenty-six have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $85.73.
In other Gilead Sciences news, Director Nicholas Moore sold 19,068 shares of Gilead Sciences stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $83.12, for a total value of $1,584,932.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at TheStreet reiterated a “buy” rating on shares of Gilead Sciences in a research note on Monday. Separately, analysts at Barclays raised their price target on shares of Gilead Sciences from $90.00 to $95.00 in a research note on Friday, February 21st. They now have an “overweight” rating on the stock. Finally, analysts at Argus raised their price target on shares of Gilead Sciences from $84.00 to $90.00 in a research note on Monday, February 10th. They now have a “buy” rating on the stock.
Gilead Sciences (NASDAQ:GILD) traded down 0.10% on Wednesday, hitting $83.865. The stock had a trading volume of 5,505,926 shares. Gilead Sciences has a 1-year low of $42.08 and a 1-year high of $84.88. The stock has a 50-day moving average of $79.56 and a 200-day moving average of $70.01. The company has a market cap of $128.7 billion and a P/E ratio of 46.38.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $0.55 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.50 by $0.05. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 20.5% on a year-over-year basis. Analysts expect that Gilead Sciences will post $3.76 EPS for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.